Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela J Oh

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Medicinal Chemistry|July 3, 2019
Discovery of Clinical Candidate (1<i>R</i>,4<i>r</i>)-4-((<i>R</i>)-2-((<i>S</i>)-6-Fluoro-5<i>H</i>-imidazo[5,1-<i>a</i>]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1Sanjeev Kumar, Jesse P Waldo, Firoz A Jaipuri, et al.
Analytical Chemistry|September 9, 2022
Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS ApproachLingyao Meng, Emily W Chan, Carl Ng, et al.
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase InhibitorsBrendan T Parr, Richard Pastor, Benjamin D Sellers, et al.
Journal of Medicinal Chemistry|June 22, 2026
Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 InhibitorsVishal A Verma, Jessica M Grandner, Brendan T Parr, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Medicinal Chemistry|July 3, 2019
Discovery of Clinical Candidate (1<i>R</i>,4<i>r</i>)-4-((<i>R</i>)-2-((<i>S</i>)-6-Fluoro-5<i>H</i>-imidazo[5,1-<i>a</i>]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1Sanjeev Kumar, Jesse P Waldo, Firoz A Jaipuri, et al.
Analytical Chemistry|September 9, 2022
Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS ApproachLingyao Meng, Emily W Chan, Carl Ng, et al.
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase InhibitorsBrendan T Parr, Richard Pastor, Benjamin D Sellers, et al.
Journal of Medicinal Chemistry|June 22, 2026
Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 InhibitorsVishal A Verma, Jessica M Grandner, Brendan T Parr, et al.
Pageof 3